Precision BioSciences Inc DTIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DTIL is a good fit for your portfolio.
News
-
Precision BioSciences to Regain Programs After Prevail Team-Up Ends
-
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
-
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
-
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
-
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
-
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
-
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
Trading Information
- Previous Close Price
- $9.84
- Day Range
- $9.85–10.60
- 52-Week Range
- $8.25–27.02
- Bid/Ask
- $10.42 / $10.54
- Market Cap
- $72.66 Mil
- Volume/Avg
- 35,702 / 133,609
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.03
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 109
Comparables
Valuation
|
Metric
|
DTIL
|
NTLA
|
EDIT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.17 | 1.95 | 1.26 |
Price/Sales | 0.03 | 53.79 | 5.22 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DTIL
|
NTLA
|
EDIT
|
|---|---|---|---|
Quick Ratio | 2.59 | 8.23 | 5.27 |
Current Ratio | 2.73 | 8.67 | 5.39 |
Interest Coverage | −21.52 | — | — |
Quick Ratio
DTIL
NTLA
EDIT
Profitability
|
Metric
|
DTIL
|
NTLA
|
EDIT
|
|---|---|---|---|
Return on Assets (Normalized) | −19.44% | −25.49% | −26.43% |
Return on Equity (Normalized) | −100.98% | −30.88% | −37.32% |
Return on Invested Capital (Normalized) | −66.71% | −31.84% | −38.19% |
Return on Assets
DTIL
NTLA
EDIT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rtzdnvmjv | Byh | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ktpbpcbb | Lvxpgmz | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tgrpnhrm | Gdtvrhl | $98.3 Bil | |
MRNA
| Moderna Inc | Jvkgllf | Fdbm | $42.7 Bil | |
ARGX
| argenx SE ADR | Bwcysjhzv | Yzbx | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Nygpmdppg | Gtdz | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vrkwngpv | Bwnfmr | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vljvjwq | Cvdlrd | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qyngxqsz | Llqxc | $12.7 Bil | |
INCY
| Incyte Corp | Pxbzyvkk | Pgffm | $11.8 Bil |